Posted by Michael Wonder on 28 Aug 2025
Rinvoq (upadacitinib) receives Health Canada notice of compliance for giant cell arteritis in adults
27 August 2025 - This marks the eighth approved indication for Rinvoq in Canada across rheumatology, gastro-enterology and dermatology.
AbbVie today announced that Health Canada has issued a Notice of Compliance for Rinvoq (upadacitinib) for the treatment of adults with giant cell arteritis, both used in combination with a tapering course of corticosteroids and as monotherapy following discontinuation of corticosteroids.
